Bayer's drug business has been on a roll, thanks to some serious growth in its 5 newest products, including the clot-fighter Xarelto and the PAH med Adempas. Now, as the company announces new nods for the vision treatment Eylea and cancer therapy Stivarga, it's also posting a 10% hike in pharma group sales for the second quarter. Report